Delving into the Latest Updates on HECN-30227 with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms

HECN30227

Target

HBV RNA

Action

inhibitors

Mechanism

HBV RNA inhibitors(HBV RNA inhibitors)

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication

Hepatitis B, Chronic

Inactive Indication-

Originator Organization

Sunshine Lake Pharma Co., Ltd.

Active Organization

Sunshine Lake Pharma Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

[Translation] A randomized, double-blind, placebo-controlled, dose-escalation, single-dose and multiple-dose Phase I clinical trial evaluating the safety, tolerability, pharmacokinetic properties, and antiviral activity of HECN30227 injection in healthy subjects and subjects with chronic hepatitis B.

1）评价HECN30227注射液在健康受试者中单次给药和在慢性乙型肝炎受试者中多次给药的安全性和耐受性；2）评价HECN30227注射液在健康受试者中单次给药和在慢性乙型肝炎受试者中多次给药的药代动力学特征与免疫原性；3）评价HECN30227注射液在慢性乙型肝炎受试者中多次给药的抗病毒活性。

[Translation]

1) Evaluate the safety and tolerability of HECN30227 injection in healthy subjects with a single dose and in subjects with chronic hepatitis B with multiple doses; 2) Evaluate the pharmacokinetic characteristics and immunogenicity of HECN30227 injection in healthy subjects with a single dose and in subjects with chronic hepatitis B with multiple doses; 3) Evaluate the antiviral activity of HECN30227 injection in subjects with chronic hepatitis B with multiple doses.

Start Date02 Dec 2025

Sponsor / Collaborator

Sunshine Lake Pharma Co., Ltd.

100 Clinical Results associated with HECN-30227

Login to view more data

100 Translational Medicine associated with HECN-30227

Login to view more data

100 Patents (Medical) associated with HECN-30227

Login to view more data

100 Deals associated with HECN-30227

Login to view more data